Vivtex

We're excited to introduce Vivtex's new scientific advisors, Tomi Sawyer, Peptide Therapeutics Expert, and Ivor Elrifi, Intellectual Property and Transactions Advisor. Tomi is the Chief Drug Hunter & President of Maestro Therapeutics, a consulting/advisory enterprise supporting peptide drug discovery, which he founded in 2019. Ivor is the Chief Executive Officer of a publicly traded biotech company, and former global chair of Cooley LLP’s patent counseling and prosecution practice. Read more about Tomi and Ivor on our page: https://lnkd.in/e7Cm2TRw

Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be discussing formulation optimization through the applications of robotic screening as an expert speaker at the Next Gen Peptide Formulation & Delivery Summit in Boston, MA from June 18-20, 2024. View the full event guide and register at https://lnkd.in/e2bWVv-S.

Vivtex's Chief Executive Officer, Maureen Deehan, will be in San Diego, CA, to attend the BIO International Convention 2024 from June 3rd to June 7th. If you would like to schedule a meeting with her during this time, drop her a message on Linkedin or via the BIO partnering system: https://lnkd.in/ebVNCbJh

We’re excited to announce that Vivtex’s Chief Executive Officer, Maureen Deehan, and Chief Scientific Officer, Thomas von Erlach, are featured in the summer issue of the European Biopharmaceutical Review (EBR) discussing the pros and challenges of creating oral biologics. Read the article here: https://lnkd.in/eKpuCvr6

Vivtex’s Chief Scientific Officer, Thomas von Erlach will be providing an overview on oral macromolecular drug delivery at the 2024 Global Drug Delivery & Formulation Summit in Berlin. Join us at the conference May 21st - May 23rd. More information at https://lnkd.in/evFJW6G4

Congratulations to Vivtex’s CEO, Maureen Deehan, for receiving the Elizabeth Elting Venture Fund Award 2024. The award recognizes highly accomplished women CEO leading the most promising emerging life sciences companies.

Vivtex CEO Maureen Deehan, will be attending BIO 2024 in June, in San Diego, CA. If you wish to send Vivtex a meeting request to speak with Maureen, please do so via the BIO partnering system: https://lnkd.in/ebVNCbJh Vivtex looks forward to joining the BIO community from 3rd to 6th June, in San Diego!

We are proud to announce that Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be a featured speaker at the upcoming Peptide Based Therapeutics Summit. Global experts will gather in Boston, MA, from 23rd -25th April to discuss the transformative potential of early phase technology in the development of next-generation peptide-based therapeutics. Here you can find the full event guide and register your place: https://lnkd.in/ebrBuzRy

We are proud to announce that Vivtex’s Chief Scientific Officer, Thomas von Erlach, will be a featured speaker at the upcoming Peptide Based Therapeutics Summit. Global experts will gather in Boston, MA, from 23rd -25th April to discuss the transformative potential of early phase technology in the development of next-generation peptide-based therapeutics. Here you can find the full event guide and register your place: https://lnkd.in/ebrBuzRy

Hot off the press: MIT study demonstrates that the Vivtex's platform technology in combination with a machine-learning algorithm can be used to predict unwanted drug-drug interactions. The work was published today in Nature Biomedical Engineering and featured by MIT News. Among the study co-authors are our Vivtex co-founders Robert Langer, Giovanni Traverso and Thomas von Erlach. https://lnkd.in/gF-49ttK